Cargando…

Post-COVID-19 neurocandidiasis

Associated with a significant morbidity and mortality, neurocandidiasis affects severely immunocompromised patients, especially if recently treated with antibiotics or corticosteroids. We present the case of a 70-year-old man admitted to an intensive care unit due to a Sars-Cov-2 pneumonia, with fev...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda, Miguel A., Sousa, Sandra C., Montes, Vera L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349610/
https://www.ncbi.nlm.nih.gov/pubmed/34368903
http://dx.doi.org/10.1007/s10072-021-05515-5
_version_ 1783735599261286400
author Miranda, Miguel A.
Sousa, Sandra C.
Montes, Vera L.
author_facet Miranda, Miguel A.
Sousa, Sandra C.
Montes, Vera L.
author_sort Miranda, Miguel A.
collection PubMed
description Associated with a significant morbidity and mortality, neurocandidiasis affects severely immunocompromised patients, especially if recently treated with antibiotics or corticosteroids. We present the case of a 70-year-old man admitted to an intensive care unit due to a Sars-Cov-2 pneumonia, with fever, coma, and multifocal neurological deficits reported 13 days after extubation. After isolation of Candida albicans in both urine and blood cultures and a brain MRI with multiple gadolinium-enhanced ring lesions, a diagnosis of neurocandidiasis was assumed and aggressive antifungal therapy started. During treatment, the patient developed a hospital-acquired pneumonia with fatal outcome.
format Online
Article
Text
id pubmed-8349610
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83496102021-08-09 Post-COVID-19 neurocandidiasis Miranda, Miguel A. Sousa, Sandra C. Montes, Vera L. Neurol Sci Covid-19 Associated with a significant morbidity and mortality, neurocandidiasis affects severely immunocompromised patients, especially if recently treated with antibiotics or corticosteroids. We present the case of a 70-year-old man admitted to an intensive care unit due to a Sars-Cov-2 pneumonia, with fever, coma, and multifocal neurological deficits reported 13 days after extubation. After isolation of Candida albicans in both urine and blood cultures and a brain MRI with multiple gadolinium-enhanced ring lesions, a diagnosis of neurocandidiasis was assumed and aggressive antifungal therapy started. During treatment, the patient developed a hospital-acquired pneumonia with fatal outcome. Springer International Publishing 2021-08-09 2021 /pmc/articles/PMC8349610/ /pubmed/34368903 http://dx.doi.org/10.1007/s10072-021-05515-5 Text en © Fondazione Società Italiana di Neurologia 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Miranda, Miguel A.
Sousa, Sandra C.
Montes, Vera L.
Post-COVID-19 neurocandidiasis
title Post-COVID-19 neurocandidiasis
title_full Post-COVID-19 neurocandidiasis
title_fullStr Post-COVID-19 neurocandidiasis
title_full_unstemmed Post-COVID-19 neurocandidiasis
title_short Post-COVID-19 neurocandidiasis
title_sort post-covid-19 neurocandidiasis
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349610/
https://www.ncbi.nlm.nih.gov/pubmed/34368903
http://dx.doi.org/10.1007/s10072-021-05515-5
work_keys_str_mv AT mirandamiguela postcovid19neurocandidiasis
AT sousasandrac postcovid19neurocandidiasis
AT montesveral postcovid19neurocandidiasis